A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy
SUPPORTIVE CARE IN CANCER, vol.15, no.10, pp.1163-1168, 2007 (SCI-Expanded)
Article / Article
SUPPORTIVE CARE IN CANCER
Science Citation Index Expanded (SCI-EXPANDED), Scopus
granisetron, antiemetic, efficacy, chemotherapy, dose comparison, RECEPTOR ANTAGONISTS, ANTIEMETIC THERAPY, PROPHYLAXIS, EFFICACY, CANCER, DEXAMETHASONE, SAFETY
Acibadem Mehmet Ali Aydinlar University Affiliated:
Background Granisetron is a safe and effective prophylaxis for nausea and vomiting associated with moderate to highly emetogenic chemotherapy. Few trials have been conducted to determine the optimal effective dose of granisetron in children with cancer. The objective of this report was to compare two doses of granisetron in patients with optic pathway tumors receiving moderately emetogenic doses of carboplatin.